Previous Close | 7.27 |
Open | 7.29 |
Bid | 7.21 x 0 |
Ask | 7.30 x 0 |
Day's Range | 7.27 - 7.32 |
52 Week Range | 6.24 - 10.00 |
Volume | |
Avg. Volume | 3,724 |
Market Cap | 91.456M |
Beta (5Y Monthly) | 0.86 |
PE Ratio (TTM) | 25.07 |
EPS (TTM) | 0.29 |
Earnings Date | Mar 07, 2023 - Mar 13, 2023 |
Forward Dividend & Yield | 0.16 (2.28%) |
Ex-Dividend Date | Nov 29, 2022 |
1y Target Est | N/A |
MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care. The product has been marketed in Europe, USA and several other markets around the world to help cancer patients with certain side effects of their treatment. BioSyent anticipates launching the
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 690,000 of its common shares (“Shares”) over a 12-month period, representing approximately 5.70% of the Shares outstanding as of December 13, 2022. The NCIB will commence on De
The Planet MicroCap Showcase: VIRTUAL taking place on December 6-8, 2022, where 49 MicroCap public companies will be presenting virtually.